TREMFYA® (guselkumab) HCP

RAPID JOINT IMPROVEMENT PROVEN TO LAST AT 2 YEARS^*

ACR20 response at Week 24 after just 4 doses (primary endpoint) and an OLE active treatment NRI post hoc analysis from Weeks 24 to 100^1-6

VIEW FULL DETAILS

EXTENSIVE RELIEF: MORE THAN JUST LASTING SKIN CLEARANCE AT 2 YEARS^*

Improvement in IGA 0/1 at Weeks 24 and 100, with additional data including PASI 90, enthesitis, dactylitis, HAQ-DI, and MDA^1-6

VIEW FULL DETAILS

PROVEN SAFETY PROFILE IN PSORIATIC DISEASE^†

Proven safety across 4 pivotal clinical trials in moderate to severe plaque psoriasis and active PsA¹

VIEW FULL DETAILS

ROBUST^‡ COVERAGE
& DEDICATED PATIENT SUPPORT

Commercial coverage as strong as Humira^® (adalimumab)—no step edit required^7§||¶

VIEW FULL DETAILS

VIEW STUDY DESIGNS

^¶The information provided does not imply comparable safety or efficacy between products and only represents access information. Humira is a registered trademark of AbbVie Inc. Please refer to each product's prescribing information for indication(s), recommend dosing, and administration.

*The same patients may not have responded at each time point. After Week 24, patients and doctors knew that all patients were on TREMFYA^® (open label with a blinded dosing interval), which may have affected the results. Year 2 represents Week 100.
^†Psoriatic disease is defined as moderate to severe plaque psoriasis and active PsA.
^‡Robust = >80% of commercially covered lives.
^§These percentages may not represent 100% of formulary lives due to data limitations.
^||"As strong as"=absolute difference less than 5%.

CONTACT YOUR
LOCAL SALES SPECIALIST

References: 1. TREMFYA^® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 3. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604-616. 5. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p-19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Presented at: Innovations in Dermatology 2021; Virtual; March 16-20, 2021. 6. Data on file. Janssen Biotech, Inc. 7. Data provided by Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of July 2022.

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

RAPID JOINT IMPROVEMENT PROVEN TO LAST AT 2 YEARS^*

EXTENSIVE RELIEF: MORE THAN JUST LASTING SKIN CLEARANCE AT 2 YEARS^*

PROVEN SAFETY PROFILE IN PSORIATIC DISEASE^†

ROBUST^‡ COVERAGE
& DEDICATED PATIENT SUPPORT

IMPORTANT SAFETY INFORMATION

INDICATIONS

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

RAPID JOINT IMPROVEMENT PROVEN TO LAST AT 2 YEARS*

EXTENSIVE RELIEF: MORE THAN JUST LASTING SKIN CLEARANCE AT 2 YEARS*

PROVEN SAFETY PROFILE IN PSORIATIC DISEASE†

ROBUST‡ COVERAGE& DEDICATED PATIENT SUPPORT

Talk with a Janssen representative

Thank you for contacting us

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

RAPID JOINT IMPROVEMENT PROVEN TO LAST AT 2 YEARS^*

EXTENSIVE RELIEF: MORE THAN JUST LASTING SKIN CLEARANCE AT 2 YEARS^*

PROVEN SAFETY PROFILE IN PSORIATIC DISEASE^†

ROBUST^‡ COVERAGE
& DEDICATED PATIENT SUPPORT